Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $27.23 Analyst target: $49.38 Upside: 81.34%
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.